Therefore, PROTACs that selectively target the non-functional BRD of SMARCA2/4 presents a potential avenue for exploiting the susceptibilities of cancer cells that rely on SMARCA2 or SMARCA4 for their survival. This evidence concerns the gene SMARCA2 and cancer.